深交所科交中心“未来行”产业对接会吸引金融机构关注

Core Insights - The event focused on promoting key projects in the biopharmaceutical sector, highlighting innovative technologies and their potential for commercialization [1][2] - The biopharmaceutical industry is recognized as a strategic emerging industry crucial for national development and high-quality growth in Jiangsu province [1][3] Group 1: Event Overview - The "Future Action" industry matchmaking event organized by the Shenzhen Stock Exchange's Science and Technology Innovation Center attracted attention from financial institutions and industry experts [1] - The event aimed to bridge the gap in the transformation of scientific achievements into practical applications, injecting new momentum into the high-quality development of the biopharmaceutical industry [1][3] Group 2: Key Projects and Technologies - Ten key projects were selected for promotion, including universal CAR-T therapy for cancer treatment, precision DNA nanomachines for cardiovascular applications, and stem cell therapies for refractory immune diseases [2] - The projects showcased significant technological advantages, particularly in the treatment of depression and immune diseases, with a strong potential for global market impact [2] Group 3: Financial Support and Collaboration - The Industrial and Commercial Bank of China (ICBC) in Nanjing has a technology loan scale exceeding 22 billion yuan, serving over 1,200 technology enterprises, including nearly 100 biopharmaceutical companies [2] - The event emphasized the need for collaboration among government, finance, enterprises, and research institutions to foster innovation in the biopharmaceutical sector [3][4] Group 4: Industry Ecosystem - Nanjing has developed a complete ecosystem for the biopharmaceutical industry, encompassing basic research, pilot incubation, and industrialization, supported by over 30 research institutions and universities [3] - The city has cultivated more than 1,200 biopharmaceutical companies across various sub-sectors, including innovative drugs and high-end medical devices [3]